Literature DB >> 19852504

Multi-gram scale synthesis of FR180204.

Samarjit Patnaik1, Harry C Dietz, Wei Zheng, Christopher Austin, Juan J Marugan.   

Abstract

A concise synthesis of the ERK inhibitor FR180204 has been developed. The synthesis consists of six operationally simple steps and can be utilized to make multi-gram quantities of FR180204.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19852504      PMCID： PMC2862695          DOI： 10.1021/jo901835m

Source DB:  PubMed          Journal:  J Org Chem        ISSN： 0022-3263            Impact factor:   4.354


  12 in total

Review 1.  Role of Ras and Mapks in TGFbeta signaling.

Authors:  K M Mulder
Journal:  Cytokine Growth Factor Rev       Date:  2000 Mar-Jun       Impact factor: 7.638

2.  Heme oxygenase activity and hemoglobin neurotoxicity are attenuated by inhibitors of the MEK/ERK pathway.

Authors:  Jing Chen-Roetling; Zhi Li; Mai Chen; Olatilewa O Awe; Raymond F Regan
Journal:  Neuropharmacology       Date:  2009-02-06       Impact factor: 5.250

3.  Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.

Authors:  Miguel F Braña; Mónica Cacho; M Luisa García; Elena P Mayoral; Berta López; Beatriz de Pascual-Teresa; Ana Ramos; Nuria Acero; Francisco Llinares; Dolores Muñoz-Mingarro; Olivier Lozach; Laurent Meijer
Journal:  J Med Chem       Date:  2005-11-03       Impact factor: 7.446

4.  Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.

Authors:  I Sircar; B L Duell; G Bobowski; J A Bristol; D B Evans
Journal:  J Med Chem       Date:  1985-10       Impact factor: 7.446

5.  Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.

Authors:  Makoto Ohori; Takayoshi Kinoshita; Mitsuru Okubo; Kentaro Sato; Akiko Yamazaki; Hiroyuki Arakawa; Shintaro Nishimura; Noriaki Inamura; Hidenori Nakajima; Masahiro Neya; Hiroshi Miyake; Takashi Fujii
Journal:  Biochem Biophys Res Commun       Date:  2005-10-14       Impact factor: 3.575

6.  Synthesis and pharmacological activity of 4-carbamoyl-6-beta-thienyl-4,5-dihydropyridazin-3-(2H)ones.

Authors:  G A Pinna; M M Curzu; E Gavini; A Mulè; G Pirisino; M Satta; A Peana
Journal:  Farmaco       Date:  1993-09

7.  Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative.

Authors:  Takayoshi Kinoshita; Masaichi Warizaya; Makoto Ohori; Kentaro Sato; Masahiro Neya; Takashi Fujii
Journal:  Bioorg Med Chem Lett       Date:  2005-10-18       Impact factor: 2.823

8.  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.

Authors:  Alex M Aronov; Christopher Baker; Guy W Bemis; Jingrong Cao; Guanjing Chen; Pamella J Ford; Ursula A Germann; Jeremy Green; Michael R Hale; Marc Jacobs; James W Janetka; Francois Maltais; Gabriel Martinez-Botella; Mark N Namchuk; Judy Straub; Qing Tang; Xiaoling Xie
Journal:  J Med Chem       Date:  2007-02-15       Impact factor: 7.446

Review 9.  The Ras-Raf-MEK-ERK pathway in the treatment of cancer.

Authors:  R A Hilger; M E Scheulen; D Strumberg
Journal:  Onkologie       Date:  2002-12

10.  Novel heterocycle-substituted pyrimidines as inhibitors of NF-kappaB transcription regulation related to TNF-alpha cytokine release.

Authors:  Hyung-Ho Ha; Jee Seon Kim; B Moon Kim
Journal:  Bioorg Med Chem Lett       Date:  2007-11-22       Impact factor: 2.823
View more
  2 in total

Review 1.  Other targeted drugs in melanoma.

Authors:  María González-Cao; Jordi Rodón; Niki Karachaliou; Jesús Sánchez; Mariacarmela Santarpia; Santiago Viteri; Sara Pilotto; Cristina Teixidó; Aldo Riso; Rafael Rosell
Journal:  Ann Transl Med       Date:  2015-10

2.  Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.

Authors:  Domenico M Taglieri; Michelle M Monasky; Ivana Knezevic; Katherine A Sheehan; Ming Lei; Xin Wang; Jonathan Chernoff; Beata M Wolska; Yunbo Ke; R John Solaro
Journal:  J Mol Cell Cardiol       Date:  2011-09-24       Impact factor: 5.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.